(3R,4R)-3-Hydroxy-4-(hydroxymethyl)-1-[(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]pyrrolidinium

Identification

Generic Name
(3R,4R)-3-Hydroxy-4-(hydroxymethyl)-1-[(4-oxo-4,4a,5,7a-tetrahydro-3H-pyrrolo[3,2-d]pyrimidin-7-yl)methyl]pyrrolidinium
DrugBank Accession Number
DB03551
Background

Not Available

Type
Small Molecule
Groups
Experimental
Structure
Weight
Average: 267.3043
Monoisotopic: 267.145715494
Chemical Formula
C12H19N4O3
Synonyms
Not Available

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UPurine nucleoside phosphorylaseNot AvailableHumans
UPurine nucleoside phosphorylaseNot AvailableMycobacterium tuberculosis
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Not Available
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.
Kingdom
Organic compounds
Super Class
Organic acids and derivatives
Class
Carboxylic acids and derivatives
Sub Class
Amino acids, peptides, and analogues
Direct Parent
Alpha amino acids and derivatives
Alternative Parents
Pyrrolopyrimidines / Hydropyrimidines / N-alkylpyrrolidines / 1,3-aminoalcohols / Pyrroles / Pyrrolines / Quaternary ammonium salts / Secondary alcohols / Trialkylamines / 1,2-aminoalcohols
show 11 more
Substituents
1,2-aminoalcohol / 1,3-aminoalcohol / 1,4,5,6-tetrahydropyrimidine / Alcohol / Aliphatic heteropolycyclic compound / Allylamine / Alpha-amino acid or derivatives / Amidine / Amine / Azacycle
show 25 more
Molecular Framework
Aliphatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
Not Available
CAS number
Not Available
InChI Key
WFVGWLHAOKEIOJ-MFQSTILNSA-O
InChI
InChI=1S/C12H18N4O3/c17-5-8-3-16(4-9(8)18)2-7-1-13-11-10(7)14-6-15-12(11)19/h1,6,8-11,13,17-18H,2-5H2,(H,14,15,19)/p+1/t8-,9+,10?,11?/m1/s1
IUPAC Name
(3R,4R)-3-hydroxy-4-(hydroxymethyl)-1-({4-oxo-3H,4H,4aH,5H,7aH-pyrrolo[3,2-d]pyrimidin-7-yl}methyl)pyrrolidin-1-ium
SMILES
[H]N1C=C(C[N+]2([H])C[C@H](O)[C@@H](CO)C2)C2N=CN([H])C(=O)C12

References

General References
Not Available
PubChem Compound
131704253
PubChem Substance
46506720
ChemSpider
4450306
PDBe Ligand
DIH
PDB Entries
1n3i / 1rsz / 2a0w / 2a0x / 2a0y / 2p4s / 3bgs / 3occ / 3of3

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.648 mg/mLALOGPS
logP-1.8ALOGPS
logP-2.9Chemaxon
logS-2.7ALOGPS
pKa (Strongest Acidic)11.49Chemaxon
pKa (Strongest Basic)7.94Chemaxon
Physiological Charge1Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count5Chemaxon
Polar Surface Area98.39 Å2Chemaxon
Rotatable Bond Count3Chemaxon
Refractivity78.6 m3·mol-1Chemaxon
Polarizability26.88 Å3Chemaxon
Number of Rings3Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterNoChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9345
Blood Brain Barrier-0.6745
Caco-2 permeable-0.6911
P-glycoprotein substrateSubstrate0.8241
P-glycoprotein inhibitor INon-inhibitor0.734
P-glycoprotein inhibitor IINon-inhibitor0.9153
Renal organic cation transporterNon-inhibitor0.7605
CYP450 2C9 substrateNon-substrate0.8327
CYP450 2D6 substrateNon-substrate0.7946
CYP450 3A4 substrateNon-substrate0.5282
CYP450 1A2 substrateNon-inhibitor0.7432
CYP450 2C9 inhibitorNon-inhibitor0.9079
CYP450 2D6 inhibitorNon-inhibitor0.9143
CYP450 2C19 inhibitorNon-inhibitor0.8516
CYP450 3A4 inhibitorNon-inhibitor0.9945
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9692
Ames testNon AMES toxic0.646
CarcinogenicityNon-carcinogens0.9014
BiodegradationNot ready biodegradable0.8977
Rat acute toxicity2.5735 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8278
hERG inhibition (predictor II)Non-inhibitor0.755
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-155.69624
predicted
DeepCCS 1.0 (2019)
[M+H]+158.05424
predicted
DeepCCS 1.0 (2019)
[M+Na]+164.9999
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Purine-nucleoside phosphorylase activity
Specific Function
The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine ...
Gene Name
PNP
Uniprot ID
P00491
Uniprot Name
Purine nucleoside phosphorylase
Molecular Weight
32117.69 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]
Kind
Protein
Organism
Mycobacterium tuberculosis
Pharmacological action
Unknown
General Function
The purine nucleoside phosphorylases catalyze the phosphorolytic breakdown of the N-glycosidic bond in the beta-(deoxy)ribonucleoside molecules, with the formation of the corresponding free purine bases and pentose-1-phosphate. Cleaves guanosine, inosine, 2'-deoxyguanosine and 2'-deoxyinosine.
Specific Function
Purine-nucleoside phosphorylase activity
Gene Name
punA
Uniprot ID
P9WP01
Uniprot Name
Purine nucleoside phosphorylase
Molecular Weight
27571.215 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [Article]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [Article]

Drug created at June 13, 2005 13:24 / Updated at June 12, 2020 16:52